JP2024037713A5 - - Google Patents

Download PDF

Info

Publication number
JP2024037713A5
JP2024037713A5 JP2023145013A JP2023145013A JP2024037713A5 JP 2024037713 A5 JP2024037713 A5 JP 2024037713A5 JP 2023145013 A JP2023145013 A JP 2023145013A JP 2023145013 A JP2023145013 A JP 2023145013A JP 2024037713 A5 JP2024037713 A5 JP 2024037713A5
Authority
JP
Japan
Prior art keywords
cancer
urothelial
cocrystal
fgfr3
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023145013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024037713A (ja
JP7541606B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2024037713A publication Critical patent/JP2024037713A/ja
Publication of JP2024037713A5 publication Critical patent/JP2024037713A5/ja
Priority to JP2024136962A priority Critical patent/JP2024153948A/ja
Application granted granted Critical
Publication of JP7541606B2 publication Critical patent/JP7541606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023145013A 2022-09-07 2023-09-07 Fgfr3阻害剤の共結晶形態 Active JP7541606B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024136962A JP2024153948A (ja) 2022-09-07 2024-08-16 Fgfr3阻害剤の共結晶形態

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
US63/404,232 2022-09-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024136962A Division JP2024153948A (ja) 2022-09-07 2024-08-16 Fgfr3阻害剤の共結晶形態

Publications (3)

Publication Number Publication Date
JP2024037713A JP2024037713A (ja) 2024-03-19
JP2024037713A5 true JP2024037713A5 (cg-RX-API-DMAC7.html) 2024-05-02
JP7541606B2 JP7541606B2 (ja) 2024-08-28

Family

ID=88204177

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023145013A Active JP7541606B2 (ja) 2022-09-07 2023-09-07 Fgfr3阻害剤の共結晶形態
JP2024136962A Pending JP2024153948A (ja) 2022-09-07 2024-08-16 Fgfr3阻害剤の共結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024136962A Pending JP2024153948A (ja) 2022-09-07 2024-08-16 Fgfr3阻害剤の共結晶形態

Country Status (18)

Country Link
US (1) US12662483B2 (cg-RX-API-DMAC7.html)
EP (1) EP4584270A1 (cg-RX-API-DMAC7.html)
JP (2) JP7541606B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250057022A (cg-RX-API-DMAC7.html)
CN (1) CN120187720A (cg-RX-API-DMAC7.html)
AR (1) AR130417A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023338199B2 (cg-RX-API-DMAC7.html)
CA (1) CA3266872A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025002467A2 (cg-RX-API-DMAC7.html)
CR (1) CR20250077A (cg-RX-API-DMAC7.html)
DO (1) DOP2025000054A (cg-RX-API-DMAC7.html)
IL (1) IL319342A (cg-RX-API-DMAC7.html)
JO (1) JOP20250053A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025002687A (cg-RX-API-DMAC7.html)
PE (1) PE20251400A1 (cg-RX-API-DMAC7.html)
TW (1) TWI862146B (cg-RX-API-DMAC7.html)
WO (1) WO2024054814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途
WO2026084690A1 (en) * 2024-10-14 2026-04-23 Eli Lilly And Company Fgfr3 inhibitor dosing regimens for use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163790B2 (en) * 2005-12-08 2012-04-24 New Form Pharmaceuticals, Inc. Metronidazole cocrystals and imipramine cocrystals
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技(苏州)有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Similar Documents

Publication Publication Date Title
CN114163457B (zh) 嘧啶并五元氮杂环化合物及其用途
AU2015306561B2 (en) Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP6804647B2 (ja) ピリミド[5,4−b]インドリジン又はピリミド[5,4−b]ピロリジン化合物、その製造方法及び用途
TWI659954B (zh) 氮雜二環式化合物之結晶
IL319342A (en) Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide
CN116283916B (zh) 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用
KR102421137B1 (ko) 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도
US20230250074A1 (en) Process for synthesis of quinazoline compounds
WO2024214019A1 (en) Tetracyclic compounds as smarca2 and/or smarca4 degraders
CN104926792B (zh) 甲硝唑衍生物及其制备方法和用途
CN112334458A (zh) 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
WO2015158244A1 (zh) 一种异羟肟酸类化合物及其在制备抑制癌细胞增殖和/或治疗癌症的药物中的应用
DK2020410T3 (en) Pyrido [2,3-d] pyrimidine derivatives, the preparation thereof and therapeutic use
CN110105356A (zh) 一种氮杂吲哚类化合物及其制备方法和用途
CN112930348B (zh) 用于制造3-[(1S)-1-咪唑并[1,2-a]吡啶-6-基乙基]-5-(1-甲基吡唑-4-基)三唑并[4,5-b]吡嗪的改进方法及其多晶型形式
AU2018234027A1 (en) Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative
CN109384784B (zh) 磺酰胺类衍生物、其制备方法及其在医药上的用途
CN103936730A (zh) 苯磺酰胺噻唑激酶抑制剂
CN118525012A (zh) 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用
CN103923081B (zh) 化合物及其制备方法和应用
CN108383849B (zh) 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
CN107129465B (zh) 芳基胍类化合物及其制备方法和用途
CN114426541B (zh) 氮杂芳基化合物及其用途
CN111039940B (zh) 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途